



## TENTH UMOS CONFERENCE / ESMO SUPPORTED MEETING

### Breast cancer as a fast moving target:

### What are the most important treatment and diagnosis updates during the last 2 years?

Belgrade, 16-17<sup>th</sup> May 2015

Best Western - Hotel M, Belgrade

<u>Scientific committee:</u>	<u>Organizing committee:</u>
<ul style="list-style-type: none"><li>· Zorica Tomasevic</li><li>· Suzana Vasovic</li><li>· Ljiljana Stamatovic</li><li>· Snezana Susnjar</li></ul>	<ul style="list-style-type: none"><li>· Marijana Milovic-Kovacevic</li><li>· Marija Ristic</li></ul>

### Meeting Program

Coffee will be served before start of the meeting

#### Day 1

May 16<sup>th</sup> 2015 Registration 8.30-9.00

*President addressing and introduction of speakers*

**9.00 - 9.45 Guidelines for the treatments of LABC and MBC ABC2 – F. Cardoso**

*Discussion 9.45-10.00*

**10.00 - 10.15 Metastatic process-basic overview –chair: S. Radulovic**

- Liquid biopsy: Tumor diagnosis and treatment monitoring in a blood test - R. Jankovic

**10.15 - 11.00 Specific metastatic sites: focus on bone metastases - chair: S. Susnjar**

- Bone marrow metastases/ impact on disease outcome –S. Susnjar
- Prevention of bone metastases : role of adjuvant bisphosphonates – T. Badovinac-Crnjevic
- Prevention of bone metastases: role of RANKL inhibitor denosumab – M. Milovic-Kovacevic

*Discussion 11.00-11.15*

**11.15 - 12.15 Why metastatic breast cancer is not curable? Part 1 – chair: Zorica Tomasevic**

- General mechanisms of drug resistance: focus on chemotherapy - Zoran Tomašević
- Mechanism of hormone drug resistance - Lj. Stamatović
- Mechanism of monoclonal antibody drug resistance: focus on trastuzumab – Zorica Tomasevic
- Mechanisms of TKIs drug resistance : focus on lapatinib – S. Vasović

*Discussion 12.15-12.30*

*Lunch 12.30.-13.30*

**13.30 - 14.15 Why metastatic breast cancer is not curable? Part 2 – chair: S. Vasovic**

**J. Gligorov**

- What is the mechanism of late metastases development?
- Immune system failure or something else? What significance has lymphocytic infiltration in the vicinity of breast cancer?
- Impact of chronic inflammation and breast cancer

*Discussion 14.15-14.30*

**14.30 - 15.15 Specific subtypes: HER2 positive BC (short overview of anti-HER2 options) – chair: Lj. Stamatovic**

**G. Curigliani:**

- Anti-HER2 vaccines
- Lapatinib and dual HER2 blockade; Pertuzumab, TDM-1
- Antibody Bio- similar drugs: to trust, doubt, or accept inevitable?

*Discussion 15.15-15.30*

**15.30 - 16.15 Specific subtypes: triple negative BC – chair: I. Božović**

- Bad news or might be not?-Aleksandra Filipovic
- Chemotherapy: is better to use platinum agents and why? –Z. Murtezani
- Biology therapy (PARP, BEV): a case dismissed? – I. Božović

*Discussion 16.15-16.30*

**17.00 - 18.30 Roche symposium**

End of day one

**Day 2**

May 17<sup>th</sup>

*8.30 - 9.00 Coffee*

**9.00 - 9.15 Special lecture: Recent advances in the prevention of chemotherapy-induced nausea and vomiting – S. Bošnjak**

**9.15 - 10.00 UMOS YOUNG ONCOLOGISTS (evaluation of specific issues) – Moderator: L. Popović**

- Really young patients (< 30yrs) (incidence, patient and treatment characteristics) - L. Popović
- Breast cancer as a chronic disease (incidence, patient and treatment characteristics) - A. Cvetanović
- The algorithm on the management of diarrhea during cancer chemotherapy – J. Dimitrijević

*Discussion 10.00 - 10.15*

*Coffee break 10.15 - 10.30*

Meeting Adjourn